<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554203</url>
  </required_header>
  <id_info>
    <org_study_id>H-22844</org_study_id>
    <nct_id>NCT00554203</nct_id>
  </id_info>
  <brief_title>Sulfasalazine and Endothelial Function</brief_title>
  <official_title>Effect of Sulfasalazine on Endothelial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experimental studies suggest that systemic inflammation leads to endothelial dysfunction and
      atherosclerosis. This study will examine the effects of the anti-inflammatory drug
      sulfasalazine on endothelial function in patients with coronary artery disease. Subjects will
      be treated with sulfasalazine or to placebo for six weeks. After a two-week rest period,
      subjects will cross over to the alternative treatment. Endothelium-dependent flow-mediated
      dilation of the brachial artery will be studied before and after each drug. We hypothesize
      that anti-inflammatory therapy will reverse endothelial dysfunction in patients with coronary
      artery disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial artery flow-mediated dilation</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum markers of inflammation</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfasalazine</intervention_name>
    <description>sulfasalazine 2 grams daily for 6 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of coronary artery disease

        Exclusion Criteria:

          -  G6PD deficiency defined by red blood cell G6PD activity assay

          -  Sulfa allergy

          -  Aspirin allergy

          -  Allergy to furosemide (lasix), hydrochlorthiazide, sulfonylureas, acetazolamide
             (Diamox) or other carbonic anhydrase inhibitors

          -  SGOT, SGPT, alkaline phosphatase, total bilirubin greater than 2 times the upper limit
             of normal

          -  WBC less than 4.0 or greater than 11.0 K/UL

          -  Platelet count less than 150 K or greater than 450K

          -  Hematocrit less than 30% 7

          -  Serum creatinine greater than 1.5 mg/dl

          -  Unstable angina or acute MI within 2 weeks

          -  Warfarin treatment

          -  Immunosuppressive treatment (methotrexate, cyclosporine, etc.)

          -  Digoxin treatment

          -  Phenytoin (Dilantin) treatment

          -  Methenamine (Mandelamine, Urex) treatment

          -  Probenecid or sulfinpyrazone (Anturane, Aprazone) treatment

          -  Porphyria

          -  Symptomatic GI obstruction

          -  GU obstruction (not including clinical evidence of benign prostatic hypertrophy)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Vita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2007</study_first_submitted>
  <study_first_submitted_qc>November 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2007</study_first_posted>
  <last_update_submitted>May 13, 2008</last_update_submitted>
  <last_update_submitted_qc>May 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfasalazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

